{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:44:18Z","timestamp":1768009458353,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Boehringer-Ingelheim","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40256-019-00359-z","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T06:33:08Z","timestamp":1561789988000},"page":"81-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS"],"prefix":"10.1007","volume":"20","author":[{"given":"Patrick","family":"Blin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dureau-Pournin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"B\u00e9nichou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelilah","family":"Abouelfath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Droz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-2817","authenticated-orcid":false,"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"issue":"9","key":"359_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","volume":"147","author":"PA Wolf","year":"1987","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147(9):1561\u20134.","journal-title":"Arch Intern Med."},{"key":"359_CR2","first-page":"CD001927","volume":"3","author":"MI Aguilar","year":"2005","unstructured":"Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;3:CD001927.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"359_CR3","doi-asserted-by":"publisher","first-page":"855-63, 63 e2","DOI":"10.1016\/j.ahj.2008.06.029","volume":"156","author":"S Goto","year":"2008","unstructured":"Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156(5):855-63, 63 e2.","journal-title":"Am Heart J."},{"issue":"3","key":"359_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/bcp.12807","volume":"81","author":"P Blin","year":"2016","unstructured":"Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol. 2016;81(3):569\u201378.","journal-title":"Br J Clin Pharmacol."},{"issue":"12","key":"359_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med."},{"issue":"10","key":"359_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med."},{"issue":"11","key":"359_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med."},{"issue":"22","key":"359_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med."},{"issue":"9921","key":"359_CR9","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet."},{"issue":"11","key":"359_CR10","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","volume":"176","author":"DJ Graham","year":"2016","unstructured":"Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176(11):1662\u201371.","journal-title":"JAMA Intern Med."},{"issue":"2","key":"359_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157\u201364.","journal-title":"Circulation."},{"key":"359_CR12","doi-asserted-by":"publisher","first-page":"i3189","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.","journal-title":"BMJ."},{"key":"359_CR13","doi-asserted-by":"crossref","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6).","DOI":"10.1161\/JAHA.116.003725"},{"issue":"5","key":"359_CR14","first-page":"975","volume":"116","author":"GY Lip","year":"2016","unstructured":"Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116(5):975\u201386.","journal-title":"Thromb Haemost."},{"issue":"12","key":"359_CR15","first-page":"907","volume":"38","author":"L Staerk","year":"2017","unstructured":"Staerk L, Fosbol EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017;38(12):907\u201315.","journal-title":"Eur Heart J."},{"issue":"11","key":"359_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jama.2017.1152","volume":"317","author":"TS Potpara","year":"2017","unstructured":"Potpara TS, Lip GY. Postapproval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation. JAMA. 2017;317(11):1115\u20136.","journal-title":"JAMA."},{"issue":"1","key":"359_CR17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/archinte.167.1.68","volume":"167","author":"PG Steg","year":"2007","unstructured":"Steg PG, Lopez-Sendon J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167(1):68\u201373.","journal-title":"Arch Intern Med."},{"issue":"9453","key":"359_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d. Lancet. 2005;365(9453):82\u201393.","journal-title":"Lancet."},{"issue":"11","key":"359_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","volume":"9","author":"J Beyer-Westendorf","year":"2011","unstructured":"Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9(11):2153\u20138.","journal-title":"J Thromb Haemost."},{"key":"359_CR20","doi-asserted-by":"publisher","first-page":"i2607","DOI":"10.1136\/bmj.i2607","volume":"353","author":"SV Wang","year":"2016","unstructured":"Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016;353:i2607.","journal-title":"BMJ."},{"key":"359_CR21","doi-asserted-by":"crossref","unstructured":"Maura G, Blotiere PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015.","DOI":"10.1161\/CIRCULATIONAHA.115.015710"},{"issue":"8","key":"359_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"6","key":"359_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/pds.3221","volume":"21","author":"MA Bernard","year":"2012","unstructured":"Bernard MA, Benichou J, Blin P, Weill A, Begaud B, Abouelfath A, et al. Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2012;21(6):573\u201383.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"25","key":"359_CR24","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med."},{"issue":"2","key":"359_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","volume":"54","author":"A Bannay","year":"2016","unstructured":"Bannay A, Chaignot C, Blotiere PO, Basson M, Weill A, Ricordeau P, et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. Med Care. 2016;54(2):188\u201394.","journal-title":"Med Care."},{"issue":"4","key":"359_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"359_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.4171","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Groenwold RH, Ali MS, Lassalle R, Robinson P, de Boer A, et al. Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2017;26(3):285\u201393.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"359_CR28","doi-asserted-by":"crossref","unstructured":"Blin P, Dureau-Pournin C, Lassalle R, Jove J, Thomas-Delecourt F, Droz-Perroteau C, et al. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. Br J Clin Pharmacol. 2017.","DOI":"10.1111\/bcp.13291"},{"issue":"1\u20132","key":"359_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000438859","volume":"74","author":"M Giroud","year":"2015","unstructured":"Giroud M, Hommel M, Benzenine E, Fauconnier J, Bejot Y, Quantin C, et al. Positive predictive value of french hospitalization discharge codes for stroke and transient ischemic attack. Eur Neurol. 2015;74(1\u20132):92\u20139.","journal-title":"Eur Neurol."},{"issue":"6","key":"359_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/fcp.12143","volume":"29","author":"J Bezin","year":"2015","unstructured":"Bezin J, Girodet PO, Rambelomanana S, Touya M, Ferreira P, Gilleron V, et al. Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam Clin Pharmacol. 2015;29(6):586\u201391.","journal-title":"Fundam Clin Pharmacol."},{"key":"359_CR31","first-page":"42","volume":"582","author":"V Gilleron","year":"2018","unstructured":"Gilleron V, Gasnier-Duparc N, Hebbrecht G. Certification des comptes: Une incitation \u00e0 la tra\u00e7abilit\u00e9 des processus de contr\u00f4le. Revue Hospitaliere de France. 2018;582:42\u20136.","journal-title":"Revue Hospitaliere de France."},{"key":"359_CR32","doi-asserted-by":"crossref","unstructured":"Bosco-L\u00e9vy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, et al. Diagnostic accuracy of the international classification of disease 10th revision codes of heart failure in administrative database Pharmacoepidemiol Drug Saf. 2018;27:in press.","DOI":"10.1002\/pds.4690"},{"issue":"1","key":"359_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25(1):1\u201321.","journal-title":"Stat Sci."},{"issue":"4","key":"359_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512\u201322.","journal-title":"Epidemiology."},{"issue":"2","key":"359_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/EDE.0000000000000581","volume":"28","author":"S Schneeweiss","year":"2017","unstructured":"Schneeweiss S, Eddings W, Glynn RJ, Patorno E, Rassen J, Franklin JM. Variable selection for confounding adjustment in high-dimensional covariate spaces when analyzing healthcare databases. Epidemiology. 2017;28(2):237\u201348.","journal-title":"Epidemiology."},{"issue":"3","key":"359_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00228-012-1334-2","volume":"69","author":"E Garbe","year":"2013","unstructured":"Garbe E, Kloss S, Suling M, Pigeot I, Schneeweiss S. High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications. Eur J Clin Pharmacol. 2013;69(3):549\u201357.","journal-title":"Eur J Clin Pharmacol."},{"issue":"Suppl 1","key":"359_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/pds.2328","volume":"21","author":"JA Rassen","year":"2012","unstructured":"Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):41\u20139.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"12","key":"359_CR38","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/aje\/kwr001","volume":"173","author":"JA Rassen","year":"2011","unstructured":"Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173(12):1404\u201313.","journal-title":"Am J Epidemiol."},{"key":"359_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc."},{"issue":"1","key":"359_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","volume":"175","author":"I Hernandez","year":"2015","unstructured":"Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18\u201324.","journal-title":"JAMA Intern Med."},{"issue":"4","key":"359_CR41","first-page":"754","volume":"116","author":"J Carmo","year":"2016","unstructured":"Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116(4):754\u201363.","journal-title":"Thromb Haemost."},{"issue":"4","key":"359_CR42","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","volume":"2","author":"K Bouillon","year":"2015","unstructured":"Bouillon K, Bertrand M, Maura G, Blotiere PO, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2(4):e150\u20139.","journal-title":"Lancet Haematol."}],"updated-by":[{"DOI":"10.1007\/s40256-021-00517-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000}}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-019-00359-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00359-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T21:27:29Z","timestamp":1694986049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-019-00359-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00359-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40256-021-00517-2","asserted-by":"object"}]},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,29]]},"assertion":[{"value":"29 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40256-021-00517-2","URL":"https:\/\/doi.org\/10.1007\/s40256-021-00517-2","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nicholas Moore has received fees from Bayer for training unrelated to this paper. Yves Cottin has received consulting fees from Bayer, Servier, Astra-Zeneca, Boehringer and Vifor Pharma. Patrick Mismetti has received consulting fees from Bristol-Myers Squibb, Pfizer and Bayer. Jacques B\u00e9nichou has no conflicts of interest. Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Regis Lassalle and C\u00e9cile Droz are employees of ADERA, the non-profit organization that provides human resources for Bordeaux PharmacoEpi. Their salaries derive from the various studies that are commissioned to Bordeaux PharmacoEpi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was required by the national healthcare authorities as a post-authorization commitment by Boehringer Ingelheim, which markets dabigatran. It was funded by an unrestricted grant from Boehringer Ingelheim. The company had an observer role and had no part in study design, implementation or analysis, the decision to publish this paper or its content. Bayer has also funded a parallel study on the same drugs under the same circumstances.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This study was authorized by the National Commission on Informatics and Liberties (CNIL) on 22 October 2015 under number 1858904. It was registered with the European Post-Authorisation Study (EUPAS) registry as EUPAS13017 () and in Clinicaltrials.gov as NCT02785354.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}